Glenmark Launches Generic Glaucoma Treatment in US
Glenmark Pharmaceuticals Inc, USA has launched Latanoprost ophthalmic solution, 0.005% (0.05 mg/mL) in the market, the Mumbai-based drug maker said in a statement.
The company's product is therapeutically equivalent to Upjohn US LLC's reference listed drug, Xalatan Ophthalmic Solution, it added.
According to IQVIA, sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution achieved annual sales of around USD 113.5 million.
"We are excited to announce the launch of our 4th ophthalmic product, Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), growing our portfolio of products within the ophthalmic channel," Marc Kikuchi, President & Business Head, North America said.
This addition highlights company's commitment to meeting market needs and providing quality solutions for customers, he added.
Shares of Glenmark were trading 1.12 per cent down at Rs 1,394.10 apiece on BSE.
You May Like To Read
MORE NEWS
US tariffs on key manufacturing hubs like China, India, and Vietnam impact Apple's...
ICRA says US tariffs won't affect Indian passenger vehicle exports, but auto component...
Commerce Minister Piyush Goyal calls on Indian startups to shift focus from delivery...
DPIIT has revised IEM guidelines, increasing the investment and turnover thresholds for...
India will adopt a cautious approach to US import tariffs, considering potential...
NSDC and WRI India have partnered to boost green skills in manufacturing, service, and...
Sebi has issued a warning letter to IIFL Capital for non-compliance with regulatory...
State-owned Bank of Baroda (BoB) reported a 12.8% rise in loan growth to Rs 12.3 lakh...
Parag Milk Foods has raised Rs 161 crore from a group of investors, including promoter...
Karnataka's food minister seeks additional food items like wheat, sugar, cooking oil,...